This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Toubi, E Articles by Golan, T D Search for Related Content PubMed PubMed Citation Articles by Toubi, E Articles by Golan, T D Social Bookmarking                         What's this?

The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients

Director, Div. Clinical Immunology and Allergy, Bnai Zion Medical Center, 47 Golomb Street, PO Box 4940, Haifa 31048, Israel Tel:(/ 972)8359253; Fax:(/ 972) 48371393.

I Rosner

M Rozenbaum

Rheumatology Unit, Bnai Zion Medical Center and Faculty of Medicine, Technion, Haifa, Israel

A Kessel

T D Golan

Division of Clinical Immunology, Technion, Haifa, Israel

Background: Although the benefit of antimalarials in the treatment of cutaneous LE is well established, the effect of combined hydroxychloroquine and quinacrine treatment in systemic lupus erythematosus with major organ involvement remains underappreciated.

Patients: Six active SLE patients (SLEDAI score > 5 points), with a mean duration of illness 9.1 yr (range 2 ± 17 yr) were started on quinacrine (100 mg/d) following failure to achieve clinical remission on a therapeutic regimen which included a maintenance dose of hydroxychloroquine (400 mg/d) together with prednisone (either 10 ± 20 mg/d or higher daily doses of this agent for short periods) and azathioprine (150 mg/d) or methotrexate (7.5 mg/week).

Outcome: In 5=6 of the patients the addition of quinacrine to the previous treatment resulted in complete remission (SLEDAI 0 ± 2 points), which persisted over the follow-up period [mean 2.2 yr (range 0.5 ± 3.5)]. During this period hydroxychloroquine and azathioprine were reduced to 200 mg/d and 100 mg/d respectively, whereas prednisone was modified as follows: in 2 patients daily administration was discontinued; in one the dose was reduced to 2.5 mg/d (from that of 20 mg/d); in 2 others the previous need for an intermittent course was avoided. However, in one out of the six patients the addition for 3 months of quinacrine to the therapeutic protocol did not result in clinical improvement and was therefore discontinued.

Conclusions: The promising results of this preliminary investigation encourages the combined use of the two antimalarial drugs in appropriate candidates. This modality may induce remission, seems to be safe and possesses a steroid sparing effect.

Key Words: antimalarials • hydroxychloroquine • quinacrine • SLE

Lupus, Vol. 9, No. 2, 92-95 (2000)
DOI: 10.1191/096120300678828082


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. C. Ang and V. P. Werth Combination Antimalarials in the Treatment of Cutaneous Dermatomyositis: A Retrospective Study Arch Dermatol, July 1, 2005; 141(7): 855 - 859. [Abstract] [Full Text] [PDF]

				E Toubi, A Kessel, I Rosner, M Rozenbaum, M Lorber, D Paran, E Sabo, and T D Golan Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE Lupus, April 1, 2003; 12(4): 297 - 301. [Abstract] [PDF]

				A Wozniacka, A Carter, and D P Mccauliffe Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit Lupus, February 1, 2002; 11(2): 71 - 81. [Abstract] [PDF]

				D D'Cruz Antimalarial therapy: a panacea for mild lupus? Lupus, March 1, 2001; 10(3): 148 - 151. [Abstract] [PDF]